Campbell Alliance Announces Executive Promotions and Organizational Changes
September 8, 2011
Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced executive promotions and organizational changes that were effective September 1, 2011.
Earlier today, Campbell Alliance announced that Nader Naeymi-Rad, formerly Chief Operating Officer, will assume the role of Chief Executive Officer. The firm is also making a range of additional changes to help drive the firm’s growth.
“As a high-growth company, we are constantly looking for ways to better align our executive management team to support the firm’s vision and growth needs. Our vision is to become a recognized ‘best in class’ firm while maintaining strong double-digit, year-over-year growth. The changes we’re announcing today are designed to help us achieve those goals,” stated Mr. Naeymi-Rad.
The additional changes include the following:
Darius Naigamwalla, formerly Practice Area Leader, Brand Management Practice, will assume the role of Managing Director, North America. In his new role, Mr. Naigamwalla will assume responsibility for managing the firm’s consulting operations across all of its geographic regions in North America.
According to Mr. Naeymi-Rad, “This move is a clear validation of the regional structure that we adopted two years ago. It has helped us achieve significant growth in our key accounts, while reducing out-of-town travel for our consultants and related expenses for our clients. With over 10 years of experience at Campbell Alliance, and a proven track record of success, I am 100% confident in Darius’ ability to lead and grow our North American consulting operations.”
Ashwin Dandekar, formerly Regional General Manager, New York, will assume the role of Practice Area Leader, Brand Management Practice.
“A trained physician, Ashwin has been with the firm for more than eight years. Ashwin is an innovator and has been instrumental in building the Brand Management Practice from the ground up. In particular Ashwin has made invaluable contributions to the Practice’s two largest offerings: the Launch Playbook™ (launch planning and management) and Innovation2Value™ (commercial planning) service lines. Brand Management is our largest practice area, and no one is better qualified to lead it,” said Mr. Naeymi-Rad.
Mark Bethers, formerly Vice President, Human Resources, will assume the role of Executive Vice President, Internal Operations. In his new role, Mr. Bethers will assume leadership of key internal functions at Campbell Alliance, including Legal, Finance, Information Technology, Project Services, Human Resources, Recruiting, Training, Facilities, and Administration.
According to Mr. Naeymi-Rad, “Mark has a unique background, which has proven particularly valuable to our firm. A CPA for the past 17 years, he began his career in professional services with a ’Big 4’ public accounting firm before continuing on to hold a range of senior-level finance and human resources positions in large and midsize biopharmaceutical companies and pharmaceutical services firms. As our Vice President of Human Resources for the past three years, Mark has proven to be highly pragmatic, an extraordinarily strategic thinker, and a visionary from an organizational standpoint. He’ll bring that kind of vision to his new, much-expanded role.”
Craig Dunkley, formerly Vice President, Marketing, will assume the title of Chief Marketing Officer. Mr. Dunkley is responsible for marketing Campbell Alliance’s services to the pharmaceutical and biotech industry. He and his team are responsible for branding, thought leadership, public and media relations, sales support, and marketing operations.
Mr. Naeymi-Rad added, “Our approach to marketing is strategic, systematic, and ROI-focused. The marketing machine Craig has built over the last ten years works extremely well. We’re excited about the new initiatives we’re conducting this year related to thought leadership, and we’re also in the midst of a major brand update initiative, which will be completed this year. Craig’s contributions in these and other areas are simply remarkable and warrant his promotion to CMO. ”
Each of these positions will report directly to the CEO, Mr. Naeymi-Rad. He added, “These changes are incredibly exciting for the firm. Not only are they the right changes to help drive our continued growth, they are also shining examples of Campbell Alliance’s meritocracy in action. As a group, the average tenure of these executives is eight years with the firm. They have played key roles in our growth, they have demonstrated incredible commitment to the firm, and they have always delivered. These promotions are richly deserved, and I can’t think of a group of leaders who is better suited to help guide Campbell Alliance into the future.”
About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced acquisitions, and any additional leverage we may incur in connection with the financing thereof, on the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; the impact of any default by any of our credit providers or swap counterparties; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability accurately forecast insurance claims within our self-insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses, including the acquisitions of i3 Global and PharmaNet Development Group, Inc., into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; and the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.